Orla antidiabetic drugs duration
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from Katzung's Pharmacology. I have enough information to provide a thorough answer on the duration of action of oral antidiabetic drugs.
Here is a comprehensive overview of oral antidiabetic drugs and their duration of action, based on Katzung's Basic and Clinical Pharmacology (16th ed.):
Oral Antidiabetic Drugs - Duration of Action
1. Sulfonylureas (Insulin Secretagogues)
These stimulate insulin release by binding to ATP-sensitive K+ channels on beta cells.
First-Generation:
| Drug | Duration of Action |
|---|---|
| Tolbutamide | 6-12 hours (shortest; given 2-3x/day) |
| Tolazamide | 12-24 hours (intermediate) |
| Chlorpropamide | Up to 60 hours (longest; given once daily) |
| Acetohexamide | 12-18 hours |
Second-Generation:
| Drug | Duration of Action |
|---|---|
| Glipizide | 10-16 hours (regular); extended-release: ~24 hours |
| Glibenclamide (Glyburide) | 18-24 hours |
| Glimepiride | ~24 hours (once daily) |
| Gliclazide | 10-15 hours (regular); modified-release: ~24 hours |
Note: Second-generation sulfonylureas have greater receptor affinity and lower effective doses. They are metabolized by the liver; metabolites are excreted renally and via bile. - Katzung's Basic and Clinical Pharmacology, 16th ed., p. 1184
2. Meglitinide Analogs (Rapid-Acting Insulin Secretagogues)
Same mechanism as sulfonylureas but shorter-acting; taken with meals.
| Drug | Duration of Action |
|---|---|
| Repaglinide | 4-7 hours (peak effect ~1 hour after ingestion) |
| Nateglinide | 1-2 hours (very short; given just before each meal) |
"Repaglinide has a fast onset of action, with a peak concentration and peak effect within approximately 1 hour after ingestion, but the duration of action is 4-7 hours." - Katzung's, p. 1186
3. Biguanides
| Drug | Duration / Dosing |
|---|---|
| Metformin | Half-life: 1.5-3 hours; given 2-3x/day. Extended-release formulation allows once-daily dosing. |
"Metformin has a half-life of 1.5-3 hours, is not bound to plasma proteins, is not metabolized, and is excreted by the kidneys as the active compound." - Katzung's, p. 1187
Maximum effective dose is ~2000 mg/day despite the recommended maximum of 2550 mg. Common schedule: 500-1000 mg twice daily.
4. Thiazolidinediones (TZDs / Glitazones)
Act via PPARgamma nuclear receptors; effects take days to weeks to manifest fully.
| Drug | Duration of Action |
|---|---|
| Pioglitazone | ~24 hours (once daily); full glycemic effect takes several weeks |
| Rosiglitazone | ~24 hours (once daily or divided) |
5. Alpha-Glucosidase Inhibitors
Act locally in the gut to delay carbohydrate absorption; taken with each meal.
| Drug | Duration of Action |
|---|---|
| Acarbose | 4-6 hours; must be taken with the first bite of each meal |
| Miglitol | 4-6 hours; taken with meals |
6. DPP-4 Inhibitors (Gliptins)
Increase endogenous GLP-1 by blocking its degradation.
| Drug | Duration of Action |
|---|---|
| Sitagliptin | ~24 hours (once daily) |
| Saxagliptin | ~24 hours (once daily) |
| Vildagliptin | ~12 hours (twice daily) |
| Alogliptin | ~24 hours (once daily) |
| Linagliptin | ~24 hours (once daily) |
7. SGLT2 Inhibitors (Gliflozins)
Block renal glucose reabsorption; also cardio- and nephroprotective.
| Drug | Duration of Action |
|---|---|
| Empagliflozin | ~24 hours (once daily) |
| Dapagliflozin | ~24 hours (once daily) |
| Canagliflozin | ~24 hours (once daily) |
8. GLP-1 Receptor Agonists (Injectable but worth comparing)
| Drug | Duration of Action |
|---|---|
| Exenatide (twice daily) | ~10 hours (peak ~2 hours) |
| Liraglutide | ~24 hours (once daily) |
| Semaglutide (oral/injectable) | ~7 days (once weekly injectable) |
| Dulaglutide | ~7 days (once weekly) |
"It [exenatide] reaches a peak concentration in approximately 2 hours with a duration of action of up to 10 hours." - Katzung's, p. 1186
Summary Table
| Class | Examples | Typical Duration |
|---|---|---|
| 1st-gen Sulfonylureas | Tolbutamide, Chlorpropamide | 6-60 hours |
| 2nd-gen Sulfonylureas | Glipizide, Glyburide, Glimepiride | 10-24 hours |
| Meglitinides | Repaglinide, Nateglinide | 1-7 hours |
| Biguanides | Metformin | 1.5-3 hr half-life; dosing 2-3x/day |
| TZDs | Pioglitazone | ~24 hours; weeks for full effect |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol | 4-6 hours (with each meal) |
| DPP-4 inhibitors | Sitagliptin, Linagliptin | ~24 hours |
| SGLT2 inhibitors | Empagliflozin, Dapagliflozin | ~24 hours |
Key clinical points:
- Chlorpropamide (60 hr duration) carries the highest risk of prolonged hypoglycemia
- Meglitinides are ideal for postprandial glucose control due to short duration
- SGLT2 inhibitors and DPP-4 inhibitors offer once-daily dosing with low hypoglycemia risk
- Metformin is first-line for type 2 DM and has additional cardiovascular/renal benefits when combined with SGLT2 inhibitors
Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition, Chapter 41
This is a shared conversation. Sign in to Orris to start your own chat.